ResearchIn-Press PreviewImmunology
Open Access | 10.1172/jci.insight.183676
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Ding, Y. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Yu, A. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Vujanac, M. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Copsel, S. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Moro, A. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Nivelo, L. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Dalzell, M. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Tchitchek, N. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by
Rosenzwajg, M.
in:
PubMed
|
Google Scholar
|
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Villarino, A. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Levy, R. in: PubMed | Google Scholar
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by
Klatzmann, D.
in:
PubMed
|
Google Scholar
|
1Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, Miami, United States of America
2Immunology-Immunopathology-Immunotherapy, Sorbonne Université, Paris, France
Find articles by Malek, T. in: PubMed | Google Scholar
Published August 7, 2025 - More info
Regulatory T cells (Tregs) are essential for peripheral tolerance and depend on TCR and IL-2R signaling for their homeostasis and function. In mice, IL-2-dependent BLIMP-1 contributes to Treg homeostasis. BLIMP-1 is a major transcriptional hub in human Tregs, but its mechanisms of action remain undefined. Here, using CRISPR/Cas9 ablation, we show that BLIMP-1 limits human Treg proliferation, but supports IL-10, CTLA4, several immune checkpoints, including CEACAM1, and Treg functional activity. BLIMP-1 restrains Treg expansion to IL-2 by downregulating CD25 and IL-2R signaling, and by enhancing CEACAM1 expression, which in turn inhibits responsiveness to CD3/CD28 signaling and activation of mTOR. Prolonged IL-2R signaling optimizes BLIMP-1 expression, supporting chromosomal opening of CEACAM1 to increased CEACAM1 expression through STAT5- and BLIMP-1-driven enhancers. Correspondingly, CEACAM1 is highly induced on Tregs from autoimmune patients undergoing low-dose IL-2 therapy, and these Tregs showed reduced proliferation. A humanized mouse model of xenogeneic graft versus host disease demonstrates that BLIMP-1 normally promotes, while CEACAM1 restrains, Treg suppressive activity. Collectively, our findings reveal that BLIMP-1 and CEACAM1 function in an IL-2-dependent feedback loop to restrain Treg proliferation and affect suppressive function. CEACAM1 also acts as a highly selective biomarker of IL-2R signaling in human T cells.